Novartis Wins U.S. FDA Approval for Heart-Failure Treatment

Updated on

Novartis AG won U.S. approval to sell a first-of-its-kind drug to treat heart failure, a leading cause of death among adults.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.